Comprehensive study on clinical responses and socioeconomic characteristics of COVID-19 patients during outbreak
- PMID: 35136759
- PMCID: PMC8797082
- DOI: 10.4103/jfmpc.jfmpc_579_21
Comprehensive study on clinical responses and socioeconomic characteristics of COVID-19 patients during outbreak
Abstract
The severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) causes coronavirus disease 2019 (COVID-19) and emerged as a new public health crisis. This RNA virus, which has an origin in bats, is phenotypically and genotypically diverse. The source of transmission is by direct inhalation or contact with infected droplets or indirect through fomites. The disease shows an average incubation period of 2 to 14 days. The general symptoms include fever, cough, sore throat, breathlessness, fatigue, and malaise, although in a few it is found to be asymptomatic. The immune response shows variation from individual to individual, which varies from pneumonia, chest pain, acute respiratory distress syndrome, and multiorgan failure leading to death. The cytokine and chemokine responses play a major role in the severity of the infection. Laboratory diagnosis is done by molecular investigations. The socioeconomic conditions of individuals also play a role in disease manifestation. Treatment is supportive with symptomatic management. Preventive measures include social distancing, use of face masks, and contact tracing. This review will present a general overview of coronavirus and describe the clinical and socioeconomic features of the COVID-19 patients. It will also introduce comprehensive data of symptomatic and asymptomatic patients among different Asian and Western countries during the current pandemic. Furthermore, it also focuses on the most up-to-date information on effective management and prevention of COVID-19.
Keywords: COVID-19; Clinical features; SARS-CoV-2; coronavirus; socioeconomic status.
Copyright: © 2021 Journal of Family Medicine and Primary Care.
Conflict of interest statement
There are no conflicts of interest.
Figures
Similar articles
-
COVID-19: a conundrum to decipher.Eur Rev Med Pharmacol Sci. 2020 May;24(10):5830-5841. doi: 10.26355/eurrev_202005_21378. Eur Rev Med Pharmacol Sci. 2020. PMID: 32495923
-
Novel coronavirus pandemic: A clinical overview.S Afr Fam Pract (2004). 2020 Jun 26;62(1):e1-e5. doi: 10.4102/safp.v62i1.5123. S Afr Fam Pract (2004). 2020. PMID: 32633997 Free PMC article. Review.
-
Potential role of interferons in treating COVID-19 patients.Int Immunopharmacol. 2021 Jan;90:107171. doi: 10.1016/j.intimp.2020.107171. Epub 2020 Nov 3. Int Immunopharmacol. 2021. PMID: 33221168 Free PMC article. Review.
-
COVID-19: a review.Monaldi Arch Chest Dis. 2020 May 14;90(2). doi: 10.4081/monaldi.2020.1298. Monaldi Arch Chest Dis. 2020. PMID: 32498503 Review.
-
The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.J Biol Regul Homeost Agents. 2021 Jan-Feb;35(1):1-4. doi: 10.23812/21-3-E. J Biol Regul Homeost Agents. 2021. PMID: 33377359
Cited by
-
Comparison of UVC Sensitivity and Dectin-2 Expression Between Malignant and Non-malignant Cells.In Vivo. 2022 Sep-Oct;36(5):2116-2125. doi: 10.21873/invivo.12937. In Vivo. 2022. PMID: 36099100 Free PMC article.
-
Prominent Anti-UVC Activity of Lignin Degradation Products.In Vivo. 2022 Nov-Dec;36(6):2689-2699. doi: 10.21873/invivo.13004. In Vivo. 2022. PMID: 36309360 Free PMC article.
References
-
- Gorbalenya AEA. Severe acute respiratory syndrome-related coronavirus:Thespecies and its viruses-a statement of the Coronavirus Study Group. BioRxiv. 2020 doi:https://doi.org/10.1101/2020.02.07.937862.
-
- WHO Coronavirus Disease (COVID-19) Dashboard. [Last accessed on 2021 Jan 15]. Available from: https://covid19.who.int/table .
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous